Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study
| Autor: | Ying feng Lu, Cheng Yin Ye, Shan yan Zhang, Xi Jin, Chan yuan Ye, Jue qing Gu, Jianhua Hu, Xiaoyan Wang, Liang Yu, Hongyu Jia, Ting Bo Liang, Guo dong Yu, Xiaopeng Yu, Lin Zheng, Yun Qing Qiu, Jiang shan Lian, Shao rui Hao, Yi da Yang, Huan Cai, Yi Min Zhang, Xiaoli Zhang, Ji Fang Sheng, Ci liang Jin, Lanjuan Li, Dai Rong Xiang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Hepatitis Viral Human Cross-sectional study Pneumonia Viral Gastroenterology Article Betacoronavirus 03 medical and health sciences 0302 clinical medicine Liver Function Tests Risk Factors Interquartile range Internal medicine Epidemiology medicine Humans Pandemics Retrospective Studies Hepatitis Hepatology medicine.diagnostic_test SARS-CoV-2 business.industry Liver Diseases COVID-19 Retrospective cohort study Middle Aged medicine.disease Pneumonia Diarrhea Cross-Sectional Studies Liver 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology medicine.symptom Coronavirus Infections business Liver function tests |
| Zdroj: | The American Journal of Gastroenterology |
| ISSN: | 1572-0241 0002-9270 |
| Popis: | Introduction Elevated liver enzyme levels are observed in patients with coronavirus disease 2019 (COVID-19); however, these features have not been characterized. Methods Hospitalized patients with COVID-19 in Zhejiang Province, China, from January 17 to February 12, 2020, were enrolled. Liver enzyme level elevation was defined as alanine aminotransferase level >35 U/L for men and 25 U/L for women at admission. Patients with normal alanine aminotransferase levels were included in the control group. Reverse transcription polymerase chain reaction was used to confirm severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and patients symptomatic with SARS-CoV-2 infection were defined as patients with COVID-19. Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were collected and compared. Results Of 788 patients with COVID-19, 222 (28.2%) patients had elevated liver enzyme levels (median [interquartile range {IQR}] age, 47.0 [35.0-55.0] years; 40.5% women). Being male, overweight, and smoking increased the risk of liver enzyme level elevation. The liver enzyme level elevation group had lesser pharyngalgia and more diarrhea than the control group. The median time from illness onset to admission was 3 days for liver enzyme level elevation groups (IQR, 2-6), whereas the median hospitalization time for 86 (38.7%) discharged patients was 13 days (IQR, 11-16). No differences in disease severity and clinical outcomes were noted between the groups. Discussion We found that 28.2% of patients with COVID-19 presented with elevated liver enzyme levels on admission, which could partially be related to SARS-CoV-2 infection. Male patients had a higher risk of liver enzyme level elevation. With early medical intervention, liver enzyme level elevation did not worsen the outcomes of patients with COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|